Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Health technology entities : Beigene, ltd. save search
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
Published: 2024-04-11 (Crawled : 10:00) - globenewswire.com
ZYME | $8.85 2.08% 2.03% 550K
|
Health Technology
|
| O: 0.77%
H: 2.61%
C: 1.96%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -1.55%
H: 0.89%
C: -1.01%
first conference report financial results
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
Published: 2024-04-08 (Crawled : 10:00) - globenewswire.com
ZYME | $8.85 2.08% 2.03% 550K
|
Health Technology
|
| O: 0.0%
H: 1.76%
C: -0.62%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.94%
H: 1.12%
C: 0.61%
association cancer research preclinical for meeting
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
Published: 2024-03-28 (Crawled : 10:00) - globenewswire.com
ZYME | $8.85 2.08% 2.03% 550K
|
Health Technology
|
| O: 0.49%
H: 2.13%
C: 1.64%
SNDX | $20.82 1.61% 1.59% 850K
|
Health Technology
|
| O: 0.48%
H: 4.36%
C: 2.67%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 1.24%
H: 0.24%
C: -0.39%
Zymeworks Announces Participation in Upcoming April 2024 Investor Conferences
Published: 2024-03-27 (Crawled : 11:00) - biospace.com/
ZYME | $8.85 2.08% 2.03% 550K
|
Health Technology
|
| O: 0.38%
H: 0.67%
C: -2.0%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.49%
H: 1.83%
C: 1.33%
Zymeworks Announces Participation in Upcoming Investor Conferences
Published: 2024-03-27 (Crawled : 10:00) - globenewswire.com
ZYME | $8.85 2.08% 2.03% 550K
|
Health Technology
|
| O: 0.38%
H: 0.67%
C: -2.0%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.49%
H: 1.83%
C: 1.33%
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
Published: 2024-03-13 (Crawled : 13:30) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 10.52%
H: 2.11%
C: -2.49%
brukinsa first collaboration max leukemia
AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024
Published: 2024-03-09 (Crawled : 20:20) - prnewswire.com
BEIGF | $14.29 -9.87% 2.1K
|
n/a
| Email alert
Add to watchlist
CCXI | $51.99 -0.04%
|
Health Technology
| Email alert
Add to watchlist
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
| Email alert
Add to watchlist
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
| Email alert
Add to watchlist
otezla research
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: 2024-03-07 (Crawled : 23:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.93%
H: 3.2%
C: 2.66%
fda brukinsa approval treatment
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-06 (Crawled : 21:00) - globenewswire.com
ZYME | $8.85 2.08% 2.03% 550K
|
Health Technology
|
| O: -6.93%
H: 9.65%
C: 0.51%
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -0.12%
H: 0.41%
C: -0.58%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.93%
H: 3.2%
C: 2.66%
year financial results
AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
Published: 2024-03-06 (Crawled : 21:00) - prnewswire.com
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.93%
H: 3.2%
C: 2.66%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.1%
H: 0.18%
C: -1.25%
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
Published: 2024-03-06 (Crawled : 12:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.54%
H: 0.46%
C: -1.09%
pipeline preclinical meeting
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
Published: 2024-03-05 (Crawled : 22:00) - globenewswire.com
ZYME | $8.85 2.08% 2.03% 550K
|
Health Technology
|
| O: 1.0%
H: 3.14%
C: 1.07%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.54%
H: 0.46%
C: -1.09%
association cancer research preclinical meeting
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Published: 2024-02-29 (Crawled : 16:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -1.36%
H: 0.0%
C: -5.91%
brukinsa leukemia
BeiGene to Present at Upcoming Investor Conferences - February 28, 2024
Published: 2024-02-28 (Crawled : 14:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -3.44%
H: 3.23%
C: 2.86%
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
Published: 2024-02-27 (Crawled : 12:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 2.93%
H: 9.05%
C: 8.94%
tevimbra fda license application
Zymeworks Announces Participation in Upcoming March 2024 Investor Conferences
Published: 2024-02-27 (Crawled : 12:00) - biospace.com/
ZYME | $8.85 2.08% 2.03% 550K
|
Health Technology
|
| O: 1.21%
H: 4.95%
C: 3.04%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 2.93%
H: 9.05%
C: 8.94%
Zymeworks Announces Participation in Upcoming Investor Conferences
Published: 2024-02-27 (Crawled : 11:00) - globenewswire.com
ZYME | $8.85 2.08% 2.03% 550K
|
Health Technology
|
| O: 1.21%
H: 4.95%
C: 3.04%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 2.93%
H: 9.05%
C: 8.94%
AMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO
Published: 2024-02-26 (Crawled : 14:00) - prnewswire.com
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 2.6%
H: 1.87%
C: 0.7%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.31%
H: 0.55%
C: -0.66%
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Published: 2024-02-26 (Crawled : 12:00) - biospace.com/
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -0.29%
H: 7.38%
C: 6.02%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 2.6%
H: 1.87%
C: 0.7%
business year financial results
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Published: 2024-02-26 (Crawled : 11:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 2.6%
H: 1.87%
C: 0.7%
lung chmp positive cancer cell treatment
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.